Market PotentialCytisinicline aims to address the significant unmet need in smoking and e-cigarette cessation, presenting a potentially valuable solution.
Product DevelopmentAchieve Life Sciences is preparing for the commercial launch of cytisinicline, showcasing confidence in its market potential.
Regulatory ApprovalThe FDA's agreement on a controlled Phase III trial, in addition to the Phase II ORCA-V1 trial, supports the submission of a supplemental new drug application for vaping cessation.